Ainos (AIMD) has provided an announcement.
Ainos, Inc. has secured a major boost for its AI Nose and point-of-care testing technologies by entering into a patent license agreement with Taiwan Carbon Nano Technology Corporation. This deal, which grants Ainos exclusive rights to key patents in exchange for 5.5 million shares of common stock, not only expands the company’s technical capabilities but also solidifies TCNT’s influence, granting them a controlling interest of approximately 63.2% in Ainos. Additionally, the company has settled a debt with Lind Global Fund II LP using both cash and stock, demonstrating Ainos’ proactive financial strategy to maintain momentum in its innovative pursuits.
For detailed information about AIMD stock, go to TipRanks’ Stock Analysis page.
